Optum, Red Ventures team on consumer health joint venture: report Bain goes big again, leading $350M round to fund oral challenger to blockbuster asthma biologics FDA clears Healthy.io’s smartphone-based AI test for early-stage kidney disease Sponsored: Decentralized clinical trials, patient experience and the role of supply chain management Teva shells out $24.8M—plus $20M in Narcan—to settle opioid litigation in San Francisco An Epic in miniature: CRISPR pioneer's startup reels in $55M to use tiny Cas for epigenetic engineering Philips scores FDA clearance for faster MRI scanning powered by AI AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cuts Market downturn dampens digital health funding, M&A in 2022. These sectors raked in the most cash Game on, Hemlibra. Novo Nordisk's attempt to snatch Roche's hemophilia crown gets serious CureVac's patent infringement case against BioNTech has $500M of 'potential upside': analyst Abbott's personalized brain stimulator earns FDA breakthrough tag for treating depression After building new plant and signing on with AbbVie, Regenxbio enters commercial phase Business Group: These are employers' key concerns following Supreme Court abortion ruling Featured Story | By Paige Minemyer Optum has quietly teamed with Red Ventures on a new joint venture focused on consumer health, according to media reports. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Bain Capital Life Sciences is at it again. Biotech’s go-to source for big-ticket financing rounds has stepped up to lead a $350 million series A round in Areteia Therapeutics, positioning the newly created startup to run phase 3 trials of an asthma candidate designed to have biologiclike efficacy in an oral dosage form. read more By Andrea Park At-home diagnostics have been a crucial weapon in the war against the COVID-19 pandemic, and after proving their mettle on that battlefield, they’re now becoming the standard for routine medical care. read more Sponsored By: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Zoey Becker In yet another opioid settlement, Teva has inked a deal with San Francisco to pay $24.8 million over 13 years, plus $20 million worth of Narcan over 10 years. read more By Nick Paul Taylor CRISPR co-inventor Stanley Qi is out with a new biotech that wants to make a big splash by going small. The startup, Epic Bio, corralled a VC syndicate willing to bet $55 million on its vision to use the smallest known Cas protein in epigenetic engineering. read more By Conor Hale Dubbed SmartScan, Philips said the program can help complete scans up to three times faster with virtually no loss in image quality. read more By Angus Liu In another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers including AstraZeneca, Eisai, Novartis, Pfizer, Roche and others. read more By Heather Landi After reaching a fever pitch in 2021, digital health funding cooled down in 2022, raising $10.3 billion across 329 deals in the first six months. Early-stage digital health companies, which are more likely to be free of 2021 valuation baggage, are likely to attract investor attention in today’s market, Rock Health reports. read more By James Waldron Hemlibra’s days as the hemophilia head honcho may be numbered. At least, that seems to be the hope of Novo Nordisk, which released back-to-back trial data for two of its own assets for the bleeding disorder over the past few days. read more By Kevin Dunleavy If its patent infringement lawsuit against BioNTech is successful, CureVac could be lined up to receive serious royalties from its fellow German mRNA pioneer, analysts with Berenberg Capital Markets said. read more By Andrea Park Abbott has earned the FDA’s acknowledgement for an ongoing project to apply its deep brain stimulation system to treatment-resistant depression. The designation gives the technology a more expedited pathway toward potential FDA clearance. read more By Kevin Dunleavy ROCKVILLE, MARYLAND—After building a new $65 million manufacturing facility and partnering with AbbVie in a $370 million deal, Maryland gene therapy biotech Regenxbio is entering a new phase as a burgeoning commercial business. The companies hope to bring a first-of-its-kind gene therapy to the market to treat wet age-related macular degeneration. read more By Paige Minemyer In the wake of the Supreme Court's ruling last month that reversed abortion protections under Roe v. Wade, employers are pushing the feds to quickly address potential volatility in health benefits. read more Resources Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 